Fluidigm Adds Gerhard Burbach to Its Board of Directors
SOUTH SAN FRANCISCO, Calif. -- January 14, 2013
Fluidigm Corporation (NASDAQ:FLDM) today announced that Gerhard F. Burbach has
been appointed to Fluidigm’s Board of Directors. Mr. Burbach will also join
the Board’s Audit and Compensation Committees.
“We are extremely pleased to have a seasoned executive of Gary Burbach’s
caliber joining the board of Fluidigm. Gary has extensive operating
experience, as well as strong strategic skills and expertise that we believe
will contribute to the continued success of Fluidigm,” said Sam Colella,
Fluidigm Chairman of the Board.
“Fluidigm is leading the charge into single-cell genomics. The company’s
extraordinary proprietary microfluidic technology automates the single-cell
workflow and lowers costs so that groundbreaking research in this exciting new
field becomes readily achievable. I look forward to joining Fluidigm’s Board
of Directors and working with the management team to bring these significant
opportunities to reality,” said Mr. Burbach.
Mr. Burbach currently serves as president, chief executive officer and
director of Thoratec Corporation, a publicly-traded company that develops,
manufactures and markets proprietary medical devices used for circulatory
Mr. Burbach has extensive experience in the medical technology industry. Prior
to joining Thoratec Corporation in January 2006, he served as president and
chief executive officer of Digirad Corporation from April 2005 to January
2006. He also has been a member of Digirad’s board of directors since 2004.
From July 2003 to April 2005, Mr. Burbach served as president and chief
executive officer of Bacchus Vascular, Inc., a developer of catheter-based
medical devices. From January 2001 to July 2003, he served as chief executive
officer of Philips Nuclear Medicine, a division of Philips Electronics, and,
before its acquisition by Philips, worked for four years for ADAC
Laboratories, most recently as president.
Mr. Burbach also spent six years with the management consulting firm of
McKinsey & Company, Inc., where he was most recently a senior engagement
manager in the firm’s healthcare practice.
Mr. Burbach has a B.S. in Industrial Engineering from Stanford University and
an M.B.A. from Harvard Business School.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to Fluidigm’s future performance, opportunities in the single-cell
genomics market, and the ability of management personnel and our board of
directors to contribute to the growth of Fluidigm’s business. These statements
involve known and unknown risks, uncertainties, and other factors that may
cause actual results to be materially different from any future results
expressed or implied by these forward-looking statements, including (among
others) risks relating to research and development activities and the growth
of new and developing markets, Fluidigm’s ability to successfully launch new
products and applications, and competition in Fluidigm’s primary markets.
Information on these and additional risks affecting Fluidigm’s business and
operating results are contained in its filings with the Securities and
Exchange Commission, including its most recently filed Quarterly Report on
Form 10-Q for the quarter ended September 30, 2012. These forward-looking
statements speak only as of the date hereof and Fluidigm disclaims any
obligation to update these statements.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems
for growth markets in the life science and agricultural biotechnology, or
Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of
instruments and consumables, including integrated fluidic circuits (IFCs),
assays and other reagents. These systems are designed to significantly
simplify experimental workflow, increase throughput and reduce costs, while
providing the excellent data quality demanded by customers. Fluidigm actively
markets four microfluidic systems, including thirteen different IFCs, to
leading academic institutions, diagnostic laboratories, and pharmaceutical,
biotechnology and Ag-Bio companies. Fluidigm products are marketed for
research purposes only (not for diagnostic use).
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo are trademarks or registered trademarks of
Fluidigm Corporation. All other trademarks are the property of their
Howard High – Press Relations
Press spacebar to pause and continue. Press esc to stop.